*Looking forward to a decade of the biopsychosocial model*

In conversations where the biopsychosocial model comes up, comments are commonly heard to the effect of: 'Well, we use it and teach it, but we don't know what it is!' The problem that we don't know exactly what the model is naturally gives rise to the worry that it isn't anything, and a decade or so ago this worry was being voiced loudly and clearly by experts in medicine generally and psychiatry in particular. [1][2][3][4] Although at first sight it is puzzling that we should use and teach something without knowing what it is, we can bear in mind that the biopsychosocial model has to do with many or all types of health conditions, professions and specialties, and so we should hardly expect it to be simple. In fact it's more likely to be complicated. Even if it were assumed that George Engel knew what the model was when he first proposed it in his 1977 paper, 5 that was nearly half a century ago, and clinical sciences and services have all changed a lot since then. So what, if anything, do we mean by it now?

Recent work on the biopsychosocial model: theory and applications to specific conditions and stages Since the vocal criticisms of the biopsychosocial model a decade or so ago, referred to above, there has been new work on the model, including a monograph 6 (with subsequent commentaries [7][8][9][10][11][12] ) and an edited volume. 13 Further, there have continued to be many references to the biopsychosocial model, or biopsychosocial factors, in published studies of specific health conditions. Casual (nonsystematic) web searches of the form 'biopsychosocial model of / factors for [name of a health condition]' generate lists of studies. [14][15][16] Studies that invoke biopsychosocial factors, with or without explicit use of the term 'biopsychosocial model', typically refer to psychosocial as well as biological factors in aetiology, course, treatment, adjustment and/or quality of life.

Particularly relevant in the present time of the COVID-19 pandemic are the clear demonstrations of the roles of multiple factorsbiological, psychosocial and sociopoliticalthat combine in complex ways to determine exposure, vaccination status, population prevalence, individual caseness, course, mortality, and longer-term recovery and quality of life. [17][18][19] This recent work suggests that the biopsychosocial model of at least specific health conditions is alive and well; moreover, it is even used for modelling infectious diseases, not only non-communicable conditions.

Further, the fact that the biopsychosocial model is thriving in specific applications suggests a response to the worry, highlighted above, that even though we use and teach the model, we don't know what it is, and perhaps it isn't anything. The response is that when using or teaching the model we do so with particular conditions and stages in mind, along with supporting data. To note, much the same would apply to using and teaching any other general model of health and disease, including the one the biopsychosocial model is usually contrasted with, the 'biomedical model'.

# What is the 'general model'?

Insofar as the content and utility of the biopsychosocial model lies in its application to specific conditions, at specific stages, what is the point of the (or a) general model? As just noted, the biopsychosocial model is usually contrasted with the 'biomedical model'. But then, also, what exactly is the biomedical model? Probably all such short expressions about models or any terminology alluding to a general approach, such as 'biological psychiatry' or 'neurosciencebased psychiatry' are ambiguous, without clear contenthow could they be otherwise, being so short? Therefore, they run the risk of being no more than memorable phrases, something like 'slogans'.

An alternative way of looking at this kind of terminology is that the terms serve as shorthand for methodological assumptions or hypotheses as to where causes and cures will be found, along with whatever evidence supports them.

In this spirit, I suggest that we can make use of the term 'biopsychosocial model' as a shorthand for methodological assumptions that causes and/or cures of specific conditions at specific stages, including matters of adjustment and quality of life, will generallyacross a wide range of conditionsinclude biological, psychological and social factors, and interactions between them. The contrast is then with the 'biomedical model', which deals with biological factors only.

Going further, it is possible to construct more theorised versions of general models or orientations that underpin practice. These theorised general models include foundationallevel characterisation of the relevant domain(s) and causation within them, and between them if more than one, in function and dysfunction. Thus, a theorised version of the biomedical model includes core concepts and principles/models of the biomedical sciences. Similarly, a theorised biopsychosocial model would include core concepts and principles/models of the biological, psychological and social sciences relevant to health and disease. 6 Two examples of foundational biopsychosocial theories are outlined in the next section, and some key theoretical aspects of the relations among psychology, psychiatry and neuroscience are briefly described later in the paper.

# Two examples of core theory in biopsychosocial health science

Two major new explanatory theories that integrate biopsychosocial factors across very wide ranges of health conditions have been developed in the past few decades: one implicates chronic stress and the other central involvement in pain perception. Both can be accommodated within the general biopsychosocial modeland, to be clear, not within the general biomedical modelillustrating how the general biopsychosocial model has applications not only to specific conditions but also transdiagnostically across a very wide range. The new theories are well-known in the literature, and I will summarise them here only to highlight their relevance to the biopsychosocial model.

The chronic stress model has been developed in explanatory epidemiology to link social determinants of health to a range of adverse health outcomes. Core interlinked pathways include the following: chronic psychological stress results from chronic lack of control over salient outcomes; chronic lack of control is associated with low resource levels (such as working poverty); it raises risk of anxiety and depression; chronic physiological arousal associated with chronic psychological stress raises the risk of immunological dysregulation and biological damage. 20,21 The chronic stress model (or set of related models) and associated data are thoroughly biopsychosocial and represent major discoveries about the aetiology of many health conditions, especially noncommunicable diseasesin some ways comparable to the great biomedical model of infectious diseases.

The second example of a new explanatory biopsychosocial theory with very wide application is about pain perception, that it involves neurobiological and psychological factors as well as peripheral physiological or structural damage. The new models of pain perception implicate the person's negative appraisals of what their pain means and the expected adverse effects on their lives, and associated central nervous system pain-processing mechanisms. 22,23 This new understanding of pain is at least neurobiopsychological, and it includes psychosocial factors to the extent that (perceived) adverse effects of pain on people's lives depend on the social context and task demands.

This new understanding of pain perception is directly relevant to conditions dominated by pain, but there is a much broader point that is relevant to the health sector as a whole, specifically to drivers of service use. The new models of pain perception incorporate pain, plus distress about pain, plus associated impairment of functioning; this complex of negative mental state and downturn in behavioural functioning is a close approximation to people 'feeling unwell' and is a main driver of referral and service use. This has implications for general medicine to be considered below.

# Implications for general medicine

The complex of pain, distress and associated impairment is a common presentation in general medicine; importantly, however, in a significant proportion of such presentations, biomedical investigations show no or insufficient detectable biological damage. In such cases, in some contexts, the presenting symptoms are called 'medically unexplained symptoms' (MUS), which means here 'biomedically unexplained'. However, and this is the main issue, biopsychosocial management for these cases is indicated by the new biopsychosocial models of pain perception but is not routinely provided.

The large scale of the problem is well-known. In a recent review, Jadhakhan and colleagues 24 summarise as follows (citations omitted):

It is estimated that MUS accounts for approximately 20% of new consultations in primary care, 52% of new referrals in secondary care and 20%-25% of all frequent attenders at medical clinics. Patients with MUS are commonly referred for multiple investigations and assessments with little benefit, so are needlessly costly for healthcare systems and account for approximately 10% of the total National Health Service (NHS) expenditure for the working-age adult population in England.

Specialties in which presentations of pain, distress and impairment with no or insufficient biomedical explanation arise include cardiology, [25][26][27] neurology, 28 and surgery for some pain presentations compared with placebo. [29][30][31] The implication is that a broader medical approach is required, and the new models of pain, distress and associated impairment suggest that this should include attention to biopsychosocial factors.

# A decade of the biopsychosocial model?

The question arises whether the new paradigms and findings of the sort reviewed above warrant a decade of the biopsychosocial model. The reference here is of course to 'the decade of the brain' in the 1990s. This followed from the development of new neuroscience technology in the 1980s, was instigated by the US Congress, and included increased funding for and public education on neurological and some psychiatric conditions and new technology. 32,33 Correspondingly, a decade of the biopsychosocial model would include increased publicity on and funding for research on biopsychosocial aetiology and prevention programmes, to include further research on social determinants of health and on mechanisms linking indices of social exclusion, chronic stress and illness, and on the identification of modifiable prevention targets. Such initiatives would come under the heading of biopsychosocial aetiology and prevention. Under the heading of illness, diagnosis and treatment, there could be increased publicity on and funding for research on pain, distress and impairment as drivers of service use across many medical specialties and on appropriate biopsychosocial management and treatment provision.

Psychiatry already includes biopsychosocial approaches, especially but not only in the context of multidisciplinary teams. Psychosocial formulations and treatments are already typical in mental health services. So what would a decade of the biopsychosocial model look like for psychiatry? An obvious point is that the 'biological' in psychiatry involves neuroscience, in contrast with the biomedical sciences that underpin biomedicine; in this sense, psychiatry has already been catered for in 'the decade of the brain'. Arguably, however, neuroscience so farincluding in that decadehas not advanced psychiatry much; see, for example, David Kingdon's 2020 paper 34 with the polemical title: Why hasn't neuroscience delivered for psychiatry? Kingdon calls for more research into psychosocial factors in psychiatry, and this is surely the right call.

On these issues, howeveron connections between psychiatry, neuroscience and the biopsychosocial -I would emphasise that neuroscience is properly understood in a broad way to include psychological and behavioural functioning (see, for example, the neuroscience programmes at Harvard (https://www.mcb.harvard.edu/undergraduate/neuroscience/) and UCL (https://www.ucl.ac.uk/research/domains/ neuroscience). This broad conceptualisation of neuroscience includes models of 'embodied cognition', that is, cognition that is environmentally involved. 35,36 The implication is that psychiatry should be concerned not only with neurobiological pathology but also with the vagaries of psychological processing and with environmental interactions. 37,38 It can be noted here that the importance of including environmental interactions in a broad understanding of neuroscience was recognised in the 'decade of the brain', which included increased funding for early childhood prevention programmes given emerging evidence of adverse early environmental effects on brain development. 32,33 Psychiatry and 'the rest of medicine'

Another context for the questions of what a decade of the biopsychosocial model would be like for medicine generally and for psychiatry particularly is that in Engel's original formulation, the relation between psychiatry and 'the rest of medicine' was a kind of proxy for the relation between the biomedical and the biopsychosocial models. This is how Engel starts his 1977 paper: 5 At a recent conference on psychiatric education, many psychiatrists seemed to be saying to medicine, 'Please take us back and we will never again deviate from the "medical model"'. For, as one critical psychiatrist put it, 'Psychiatry has become a hodgepodge of unscientific opinions, assorted philosophies and "schools of thought," mixed metaphors, role diffusion, propaganda, and politicking for "mental health" and other esoteric goals'. In contrast, the rest of medicine appears neat and tidy. It has a firm base in the biological sciences [. . .] and a record of astonishing achievement in elucidating mechanisms of disease and devising new treatments.

Engel is on his way to recommending the biopsychosocial model, with the implication that psychiatry's involvement with the psychosocial and not only the biological puts it ahead of the curve, not behind.

At the start of his paper he sets up the 'medical model' as a target, but more precisely his target is medicine 'with a firm base in the biological sciences' (as in the above quote), i. e. biological medicine (biomedicine) and the 'biomedical model'. This is consistent with the full title of the paper -'The need for a new medical model: a challenge for biomedicine'and Engel soon switches to this terminology of biomedical and biomedicine. To some extent this is a terminological issue, but more importantly it leaves open the possibility that medicine and its 'medical model' have always been biopsychosocial and to a great extent still are. On this point, biomedicine is not itself a medical specialty but rather a class of biological models of health and disease and associated technology for prevention, detection and treatment, which are more or less applicable in particular medical specialties. General practice and some medical specialties such as psychiatry are well-known to need a broader biopsychosocial approach. If anyone had any doubt that the management of public health requires biological-psychological-behavioural-social(-political-economic) modelling, this would have been removed by what we have seen in the current COVID-19 pandemic. However, as indicated above, accumulating evidence suggests that even medical specialties with records of astonishing biomedical achievements need a biopsychosocial extension to accommodate significant proportions of their patients.

Continuing to develop the main point, Engel at the start of his paper turns the criticism of psychiatrythat it uses biopsychosocial management as opposed to the precision of the rest of medicine using biomedical managementon its head. To continue the quote from Engel's paper 5 (p.129; text in brackets added):

It would seem that psychiatry would do well to emulate its sister medical disciplines by finally embracing once and for all the [bio]medical model of disease. But I do not accept such a premise. Rather, I contend that all medicine is in crisis and, further, that medicine's crisis derives from the same basic fault as psychiatry's, namely, adherence to a model of disease [i.e. the biomedical model] no longer adequate for the scientific tasks and social responsibilities of either medicine or psychiatry.

In this paper I have tracked Engel's approach. Rather than special pleading for psychiatry, or calls for it to be exclusively biological, like (bio)medicine, or an applied physicochemical neuroscience that doesn't include psychological and psychosocial factors, I have highlighted medicine's apparent need to be more biopsychosocial, like psychiatry. The biopsychosocial model, formalised by Engel in 1977, is at its core an acknowledgement that biological, psychological and social factors causally influence health and disease. 1 The word 'model' is broadly defined by Engel as 'nothing more than a belief system utilized to explain natural phenomena, to make sense out of what is puzzling or disturbing'. In this sense, 'paradigm' may be a more appropriate term. 2 Indeed, a paradigm shift in psychiatry has occurred since Engel's original paper, with a biopsychosocial framing now cemented in education, training and the Royal College of Psychiatrists' core values. 3 Despite its widespread adoption, the model is far from uncontroversial. Criticisms are multilevelled, from philosophical underpinnings through to application in clinical practice. Below is an assessment of the fundamental challenges the biopsychosocial model faces. Although the model is not dead in any paradigm-shifting sense, significant challenges remain in translating it to practice effectively, requiring more than mere statements of value.

# About the author

1. Derek

[[1]](#footnote-2)

* 1. Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

* 1. Declaration of interest

None.

1. ‘Engels, and the side of the angels’. MCEngel . *Lancet* 2005. 365 (9478) p. . (Engel MC. Engels, and the side of the angels. Lancet 2005; 365(9478): 2169-70.)
2. ‘The rise and fall of the biopsychosocial model’. SNGhaemi . *British Journal of Psychiatry* *Br J Psychiatry* 0007-1250 1472-1465 2009. Royal College of Psychiatrists. 195 (1) p. . (Ghaemi SN. The rise and fall of the biopsychosocial model. Br J Psychiatry 2009; 195: 3-4.)
3. *The Rise and Fall of the Biopsychosocial Model: Reconciling Art and Science in Psychiatry*, SNGhaemi . 2010. Johns Hopkins University Press. (Ghaemi SN. The Rise and Fall of the Biopsychosocial Model: Reconciling Art and Science in Psychiatry. Johns Hopkins University Press, 2010.)
4. ‘The Rise and Fall of the Biopsychosocial Model: Reconciling Art and Science in Psychiatryby GhaemiS. Nassir . Baltimore, Johns Hopkins University Press, 2010, 253pp., $50.00.’. KennethSKendler . *American Journal of Psychiatry* *AJP* 0002-953X 1535-7228 2010. American Psychiatric Association Publishing. 167 (8) p. . (Kendler KS. The rise and fall of the biopsychosocial model: reconcil- ing art and science in psychiatry. Am J Psychiatry 2010; 167(8): 999-1000.)
5. ‘The Need for a New Medical Model: A Challenge for Biomedicine’. GeorgeEEngel . *Science* *Science* 0036-8075 1095-9203 1977. American Association for the Advancement of Science (AAAS). 196 (4286) p. . (Engel GE. The need for a new medical model: a challenge for biomedi- cine. Science 1977; 196: 129-36.)
6. *The Biopsychosocial Model of Health and Disease*, DerekBolton , GrantGillett . 2019. Springer International Publishing. (Bolton D, Gillett G. The Biopsychosocial Model of Health and Disease: New Philosophical and Scientific Developments. Springer Open Access, 2019.)
7. ‘Book symposium on the biopsychosocial model of health and disease. Introduction’. MCAmoretti , ELalumera . *EuJAP* 2021. 17 (2) p. . (Amoretti MC, Lalumera E. Book symposium on the biopsychosocial model of health and disease. Introduction. EuJAP 2021; 17(2): (M1)5-8.)
8. ‘From Engel to Enactivism’. AwaisAftab , KristopherNielsen . *European journal of analytic philosophy* *EuJAP* 1845-8475 1849-0514 2021. Faculty of Humanities and Social Sciences University of Rijeka. 17 (2) p. . (Aftab A, Nielsen K. From Engel to enactivism: contextualizing the biop- sychosocial model. EuJAP 2021; 17(2): 5-22.)
9. ‘Centrifugal and Centripetal Thinking About the Biopsychosocial Model in Psychiatry’. KathrynTabb . *European journal of analytic philosophy* *EuJAP* 1845-8475 1849-0514 2021. Faculty of Humanities and Social Sciences University of Rijeka. 17 (2) p. . (Tabb K. Centrifugal and centripetal thinking about the biopsychosocial model in psychiatry. EuJAP 2021; 17(2): (M3)5-28.)
10. ‘How to Be a Holist Who Rejects the Biopsychosocial Model’. DO'leary . *European journal of analytic philosophy* *EuJAP* 1845-8475 1849-0514 2021. Faculty of Humanities and Social Sciences University of Rijeka. 17 (2) p. . (O'Leary D. How to be a holist who rejects the biopsychosocial model. EuJAP 2021; 17(2): (M4)5-20.)
11. ‘Causation and Causal Selection in the Biopsychosocial Model of Health and Disease’. HaneHMaung . *European journal of analytic philosophy* *EuJAP* 1845-8475 1849-0514 2021. Faculty of Humanities and Social Sciences University of Rijeka. 17 (2) p. . (Maung HH. Causation and causal selection in the biopsychosocial model of health and disease. EuJAP 2021; 17(2): (M5)5-27.)
12. ‘The Biopsychosocial Model of Health and Disease’. DerekBolton 0000-0003-4192-1861 . *European journal of analytic philosophy* *EuJAP* 1845-8475 1849-0514 2021. Faculty of Humanities and Social Sciences University of Rijeka. 17 (2) p. . (Bolton D. The biopsychosocial model of health and disease: responses to the 4 commentaries. EuJAP 2021; 17(2): (M6)6-26.)
13. ‘Psychiatry Reborn: Biopsychosocial psychiatry in modern medicine’. JSavulescu , RRoache , WDavies . *Psychiatry Reborn: Biopsychosocial Psychiatry in Modern Medicine*, 2020. Oxford University Press. (Savulescu J, Roache R, Davies W (eds). Psychiatry Reborn: Biopsychosocial Psychiatry in Modern Medicine. Oxford University Press, 2020.)
14. ‘Psychosocial Well-Being and HIV-Related Immune Health Outcomes among HIV-Positive Older Adults: Support for a Biopsychosocial Model of HIV Stigma and Health’. HJonathonRendina 0000-0002-0148-2852 , LaurelWeaver , BrettMMillar , JonathanLópez-Matos , JeffreyTParsons 0000-0002-6875-7566 . <https://doi.org/10.1177/2325958219888462> *Journal of the International Association of Providers of AIDS Care (JIAPAC)* *J Int Assoc Provid AIDS Care* 2325-9582 2019. SAGE Publications. 18 p. 232595821988846. (Rendina HJ, Weaver L, Millar BM, López-Matos J, Parsons JT. Psychosocial well-being and HIV-related immune health outcomes among HIV-positive older adults: support for a biopsychosocial model of HIV stigma and health. J Int Assoc Provid AIDS Care 2019. Available from: https://doi.org/10.1177/2325958219888462.)
15. ‘Risk factors for excessive gestational weight gain in a UK population: a biopsychosocial model approach’. SMGaray , LASumption , RMPearson , RMJohn . *BMC Pregnancy and Childbirth* *BMC Pregnancy Childbirth* 1471-2393 2021. Springer Science and Business Media LLC. 21 (1) p. 43. (Garay SM, Sumption LA, Pearson RM, John RM. Risk factors for exces- sive gestational weight gain in a UK population: a biopsychosocial model approach. BMC Pregnancy Childbirth 2021; 21: 43.)
16. ‘Biopsychosocial predictors of depressive symptoms in the perimenopause—findings from the Swiss Perimenopause Study’. JasmineWilli , HannahSüss , JessicaGrub , UlrikeEhlert . *Menopause* 1530-0374 2021. Ovid Technologies (Wolters Kluwer Health). 28 (3) p. . (Willi J, Süss H, Grub J, Ehlert U. Biopsychosocial predictors of depres- sive symptoms in the perimenopause-findings from the Swiss Perimenopause Study. Menopause 2021; 28(3): 247-54.)
17. ‘Biopsychosocial Processes of Health and Disease During the COVID-19 Pandemic’. WillemJKop . *Psychosomatic Medicine* *Psychosom Med* 0033-3174 1534-7796 2021. Ovid Technologies (Wolters Kluwer Health). 83 (4) p. . (Kop WJ. Biopsychosocial processes of health and disease during the COVID-19 pandemic. Psychosom Med 2021; 83(4): 304-8.)
18. ‘Managing the COVID-19 Pandemic: Biopsychosocial Lessons Gleaned From the AIDS Epidemic’. PerryNHalkitis . *Journal of Public Health Management and Practice* 1078-4659 2021. Ovid Technologies (Wolters Kluwer Health). 27 (1) p. . (Halkitis PN. Managing the COVID-19 pandemic: biopsychosocial les- sons gleaned from the AIDS epidemic. J Public Health Manag Pract 2021; 27: S39-42.)
19. ‘Why the biopsychosocial model needs to be the underpinning philosophy in rehabilitation pathways for patients recovering from COVID-19’. ThomasWWainwright 0000-0001-7860-2990 , MatthewLow . *Integrated Healthcare Journal* *Integ Health J* 2399-5351 2020. BMJ. 2 (1) p. e000043. (Wainwright TW, Low M. Why the biopsychosocial model needs to be the underpinning philosophy in rehabilitation pathways for patients recovering from COVID-19. Integr Healthc J 2020; 2(1): e000043.)
20. ‘Burden of Psychosocial Adversity and Vulnerability in Middle Age: Associations With Biobehavioral Risk Factors and Quality of Life’. AndrewSteptoe , MichaelMarmot . *Psychosomatic Medicine* 0033-3174 2003. Ovid Technologies (Wolters Kluwer Health). 65 (6) p. . (Steptoe A, Marmot M. Burden of psychosocial adversity and vulner- ability in middle age: associations with biobehavioral risk factors and quality of life. Psychosom Med 2003; 65: 1029-37.)
21. ‘Health, pre-disease and critical transition to disease in the psycho-immune-neuroendocrine network: Are there distinct states in the progression from health to major depressive disorder?’. NjcJ CStapelberg , DLNeumann , DShum , JPHeadrick . *Physiology & Behavior* *Physiology & Behavior* 0031-9384 2019. Elsevier BV. 198 p. . (Stapelberg NJC, Neumann DL, Shum D, Headrick JP. Health, pre-disease and critical transition to disease in the psycho-immune-neuroendocrine network: are there distinct states in the progression from health to major depressive disorder? Physiol Behav 2019; 198: 108-19.)
22. ‘Pain catastrophizing: a critical review’. PhillipJQuartana , ClaudiaMCampbell , RobertREdwards . *Expert Review of Neurotherapeutics* *Expert Review of Neurotherapeutics* 1473-7175 1744-8360 2009. Informa UK Limited. 9 (5) p. . (Quartana PJ, Campbell CM, Edwards RR. Pain catastrophizing: a critical review. Expert Rev Neurother 2009; 9(5): 745-58.)
23. ‘The important role of CNS facilitation and inhibition for chronic pain’. RolandStaud . *International Journal of Clinical Rheumatology* *International Journal of Clinical Rheumatology* 1758-4272 2013. OMICS Publishing Group. 8 (6) p. . (Staud R. The important role of CNS facilitation and inhibition for chronic pain. Int J Clin Rheumatol 2013; 8(6): 639-46.)
24. ‘Prevalence of medically unexplained symptoms in adults who are high users of health care services: a systematic review and meta-analysis protocol’. FerozkhanJadhakhan , OanaCLindner , AmyBlakemore 0000-0003-0972-100X , ElspethGuthrie 0000-0002-5834-6616 . *BMJ Open* *BMJ Open* 2044-6055 2019. BMJ. 9 (7) p. e027922. (Jadhakhan F, Lindner OC, Blakemore A, Guthrie E. Prevalence of med- ically unexplained symptoms in adults who are high users of health care services: a systematic review and meta-analysis protocol. BMJ Open 2019; 9(7): e027922.)
25. ‘How effective are rapid access chest pain clinics? Prognosis of incident angina and non-cardiac chest pain in 8762 consecutive patients’. NSekhri , GSFeder , CJunghans , HHemingway , ADTimmis . *Heart* *Heart* 1355-6037 2007. BMJ. 93 (4) p. . (Sekhri N, Feder GS, Junghans C, Hemingway H, Timmis AD. How effective are rapid access chest pain clinics? Prognosis of incident angina and non-cardiac chest pain in 8762 consecutive patients. Heart 2007; 93: 458-63.)
26. ‘The rapid access chest pain clinic: unmet distress and disability’. EMMarks , JBChambers , VRussell , LBryan , MSHunter . *QJM* *QJM* 1460-2725 1460-2393 2014. Oxford University Press (OUP). 107 (6) p. . (Marks EM, Chambers JB, Russell V, Bryan L, Hunter MS. The rapid access chest pain clinic: unmet distress and disability. Q J Med 2014; 107: 429-34.)
27. ‘First time referral reasons, diagnoses and 10-year follow-up of patients seen at a Dutch fast lane outpatient cardiology clinic’. TLenderink , EjmJ MBalkestein . *Netherlands Heart Journal* *Neth Heart J* 1568-5888 1876-6250 2019. Springer Science and Business Media LLC. 27 (7-8) p. . (Lenderink T, Balkestein EJM. First time referral reasons, diagnoses and 10-year follow-up of patients seen at a Dutch fast lane outpatient car- diology clinic. Neth Heart J 2019; 27: 354-61.)
28. ‘Symptoms ‘unexplained by organic disease’ in 1144 new neurology out-patients: how often does the diagnosis change at follow-up?’. JonStone , ACarson , RDuncan , RColeman , RRoberts , CWarlow , CHibberd , GMurray , RCull , APelosi , JCavanagh , KMatthews , RGoldbeck , RSmyth , JWalker , ADMacmahon , MSharpe . *Brain* 0006-8950 1460-2156 2009. Oxford University Press (OUP). 132 (10) p. . (Stone J, Carson A, Duncan R, Coleman R, Roberts R, Warlow C, et al. Symptoms 'unexplained by organic disease' in 1144 new neurology out- patients: how often does the diagnosis change at follow-up? Brain 2009; 132: 2878-88.)
29. ‘Use of placebo controls in the evaluation of surgery: systematic review’. KWartolowska , AJudge , SHopewell , GSCollins , BjfJ FDean , IRombach , DBrindley , JSavulescu , DJBeard , AJCarr . *BMJ* *BMJ* 1756-1833 2014. BMJ. 348 (may21 2) p. . (Wartolowska K, Judge A, Hopewell S, Collins GS, Dean BJF, Rombach I, et al. Use of placebo controls in the evaluation of surgery: systematic review. BMJ 2014; 348: g3253.)
30. ‘To what extent are surgery and invasive procedures effective beyond a placebo response? A systematic review with meta-analysis of randomised, sham controlled trials’. WayneBJonas , CindyCrawford , LuanaColloca , TedJKaptchuk , BruceMoseley , FranklinGMiller , LeventeKriston , KlausLinde , KarinMeissner . *BMJ Open* *BMJ Open* 2044-6055 2015. BMJ. 5 (12) p. e009655. (Jonas WB, Crawford C, Colloca L, Kaptchuk T, Moseley B, Miller FG, et al. To what extent are surgery and invasive procedures effective beyond a placebo response? A systematic review with meta-analysis of randomised, sham controlled trials. BMJ Open 2015; 5: e009655.)
31. ‘Sham Surgery in Orthopedics: A Systematic Review of the Literature’. AdriaanLouw , InaDiener , CésarFernández-De-Las-Peñas , EmilioJPuentedura . *Pain Medicine* *Pain Med* 1526-2375 1526-4637 2017. Oxford University Press (OUP). 18 (4) p. pnw164. (Louw A, Diener I, Fernández-de-las-Peñas C, Puentedura EJ. Sham sur- gery in orthopedics: a systematic review of the literature. Pain Med 2017; 18(4): 736-50.)
32. ‘Assessing the Decade of the Brain’. EdwardGJones , LorneMMendell . *Science* *Science* 0036-8075 1095-9203 1999. American Association for the Advancement of Science (AAAS). 284 (5415) p. . (Jones EG, Mendell LM. Assessing the decade of the brain. Science 1999; 284: 739.)
33. ‘Unsolved Problems of Brain Trauma’. PrakashNTandon . *Neurology India* *Neurol India* 0028-3886 2000. Medknow. 68 (3) p. 534. (Tandon PN. The decade of the brain: a brief review. Neurol India 2000; 48(3): 199-207.)
34. ‘Why hasn't neuroscience delivered for psychiatry?’. DavidKingdon 0000-0002-8913-0906 . *BJPsych Bulletin* *BJPsych Bull* 2056-4694 2056-4708 2020. Royal College of Psychiatrists. 44 (3) p. . (Kingdon D. Why hasn't neuroscience delivered for psychiatry? BJPsych Bull 2020; 44(3): 107-9.)
35. ‘The embodied brain: towards a radical embodied cognitive neuroscience’. JulianKiverstein , MarkMiller . *Frontiers in Human Neuroscience* *Front. Hum. Neurosci.* 1662-5161 2015. Frontiers Media SA. 9 p. 237. (Kiverstein J, Miller M. The embodied brain: towards a radical embodied cognitive neuroscience. Front Hum Neurosci 2015; 9: 237.)
36. ‘From cognitivism to autopoiesis: towards a computational framework for the embodied mind’. MicahAllen 0000-0001-9399-4179 , KarlJFriston 0000-0001-7984-8909 . *Synthese* *Synthese* 0039-7857 1573-0964 2018. Springer Science and Business Media LLC. 195 (6) p. . (Allen M, Friston KJ. From cognitivism to autopoiesis: towards a compu- tational framework for the embodied mind. Synthese 2018; 195: 2459-82.)
37. ‘Precision Psychiatry’. KarlJFriston 0000-0001-7984-8909 . *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging* *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging* 2451-9022 2017. Elsevier BV. 2 (8) p. . (Friston KJ. Precision psychiatry. Biol Psychiatry Cogn Neurosci Neuroimaging 2017; 2: 640-3.)
38. ‘Neurophilosophy: neuroscience, non-reductionism & psychiatry’. NPoole , DBolton . *Handbook of Neuroscience for Psychiatrists*, NAgrawal , NPoole (eds.) Oxford University Press. (in press) (Poole N, Bolton D. Neurophilosophy: neuroscience, non-reductionism & psychiatry. In Handbook of Neuroscience for Psychiatrists (eds N Agrawal, Poole N). Oxford University Press, in press.)

1. https://doi.org/10.1192/bjb.2022.34 Published online by Cambridge University Press [↑](#footnote-ref-2)